Advertisement
Table 4 Univariate analysis of patient and dosimetric characteristics and risk of radiation pneumonitis (n = 130)
| Characteristic | 0–1 RP | Grade 2–3 RP | P Value |
|---|---|---|---|
| No. of Patients (%) | No. of Patients (%) | ||
| Sex | 0.882 | ||
| Male | 59 (51.3) | 8 (53.3) | |
| Female | 56 (48.7) | 7 (46.7) | |
| Age | 0.310 | ||
| ≥74 years | 62 (53.9) | 6 (40.0) | |
| <74 years | 53 (46.1) | 9 (60.0) | |
| COPD stage | 0.154 | ||
| 0–II | 62 (53.9) | 11 (73.3) | |
| III–IV | 53 (46.1) | 4 (26.7) | |
| History of other type of cancer | 0.440 | ||
| Yes | 34 (29.6) | 3 (20.0) | |
| No | 81 (70.4) | 12 (80.0) | |
| ECOG score before SABR | 0.711 | ||
| 0–1 | 71 (61.7) | 10 (66.7) | |
| 2–3 | 44 (38.3) | 5 (33.3) | |
| Gross tumor volume, cm3 | 0.375 | ||
| ≥9.6 | 55 (47.8) | 9 (60.0) | |
| <9.6 | 60 (52.2) | 6 (40.0) | |
| Planning target volume, cm3 | 0.151 | ||
| ≥73.2 | 54 (47.0) | 10 (66.7) | |
| <73.2 | 61 (53.0) | 5 (33.3) | |
| Tumor location | 0.471 | ||
| Peripheral | 106 (92.2) | 13 (86.7) | |
| Central | 9 (7.8) | 2 (13.3) | |
| Total lung volume* | |||
| V5 | < 0.001 | ||
| ≥ 20.2% | 51 (44.3) | 14 (93.3) | |
| < 20.2% | 64 (55.7) | 1 (6.7) | |
| V10 | < 0.001 | ||
| ≥ 14.3% | 51 (44.3) | 14 (93.3) | |
| < 14.3% | 64 (55.7) | 1 (6.7) | |
| V15 | 0.003 | ||
| ≥ 11.0% | 52 (45.2) | 13 (86.7) | |
| < 11.0% | 63 (54.8) | 2 (13.3) | |
| V20 | 0.055 | ||
| ≥ 8.5% | 54 (47.0) | 11 (73.3) | |
| < 8.5% | 61 (53.0) | 4 (26.7) | |
| V25 | 0.055 | ||
| ≥ 6.4% | 54 (47.0) | 11 (73.3) | |
| < 6.4% | 61 (53.0) | 4 (26.7) | |
| V30 | 0.003 | ||
| ≥ 5.0% | 52 (45.2) | 13 (86.7) | |
| < 5.0% | 63 (54.8) | 2 (13.3) | |
| V35 | 0.003 | ||
| ≥ 3.9% | 52 (45.2) | 13 (86.7) | |
| < 3.9% | 63 (54.8) | 2 (13.3) | |
| V40 | 0.013 | ||
| ≥ 3.1% | 53 (46.1) | 12 (80.0) | |
| < 3.1% | 62 (53.9) | 3 (20.0) | |
| Mean dose to total lung volume | 0.013 | ||
| ≥ 5.05 Gy | 53 (46.1) | 12 (80.0) | |
| < 5.05 Gy | 62 (53.9) | 3 (20.0) | |
| Ipsilateral lung volume† | |||
| V5 | < 0.001 | ||
| ≥ 37.7% | 51 (44.3) | 14 (93.3) | |
| < 37.7% | 64 (55.7) | 1 (6.7) | |
| V10 | < 0.001 | ||
| ≥ 28.5% | 51 (44.3) | 14 (93.3) | |
| < 28.5% | 64 (55.7) | 1 (6.7) | |
| V15 | < 0.001 | ||
| ≥ 21.9% | 51 (44.3) | 14 (93.3) | |
| < 21.9% | 64 (55.7) | 1 (6.7) | |
| V20 | < 0.001 | ||
| ≥ 16.9% | 51 (44.3) | 14 (93.3) | |
| < 16.9% | 64 (55.7) | 1 (6.7) | |
| V25 | 0.003 | ||
| ≥ 13.1% | 52 (45.2) | 13 (86.7) | |
| < 13.1% | 63 (54.8) | 2 (13.3) | |
| V30 | 0.013 | ||
| ≥ 10.4% | 53 (46.1) | 12 (80.0) | |
| < 10.4% | 62 (53.9) | 3 (20.0) | |
| V35 | 0.003 | ||
| ≥ 8.1% | 52 (45.2) | 13 (86.7) | |
| < 8.1% | 63 (54.8) | 2 (13.3) | |
| V40 | 0.013 | ||
| ≥ 6.3% | 53 (46.1) | 12 (80.0) | |
| < 6.3% | 62 (53.9) | 3 (20.0) | |
| Mean dose to ipsilateral lung volume | < 0.001 | ||
| ≥9.14 Gy | 51 (44.3) | 14 (93.3) | |
| <9.14 Gy | 64 (55.7) | 1 (6.7) | |
